Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study

Reuters12-11

<a href="https://laohu8.com/S/PSNL">Personalis</a> NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study

Personalis, Inc. announced the publication of results from a major clinical study utilizing its NeXT Personal® test for ultrasensitive detection of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC). The study, published in the journal Cell, analyzed 431 NSCLC patients over a median of more than five years and demonstrated that the NeXT Personal test provides highly sensitive and specific detection of circulating tumor DNA (ctDNA) from diagnosis through long-term surveillance. Key findings include the ability to detect residual and recurrent cancer at multiple stages of patient care, with approximately 36-43% of detections in the ultrasensitive range. Additionally, the study found that patients who did not clear ctDNA during adjuvant chemotherapy were more than five times as likely to experience relapse compared to those who cleared ctDNA. The results have already been published and presented in Cell.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211863347) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590511875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590511875","market":"fut","top_or_hot":-1,"title":"Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Personalis, Inc. announced the publication of results from a major clinical study utilizing its NeXT Personal® test for ultrasensitive detection of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC). The study, published in the journal Cell, analyzed 431 NSCLC patients over a median of more than five years and demonstrated that the NeXT Personal test provides highly sensitive and specific detection of circulating tumor DNA (ctDNA) from diagnosis through long-term surveillance. Key findings include the ability to detect residual and recurrent cancer at multiple stages of patient care, with approximately 36-43% of detections in the ultrasensitive range. Additionally, the study found that patients who did not clear ctDNA during adjuvant chemotherapy were more than five times as likely to experience relapse compared to those who cleared ctDNA. The results have already been published and presented in Cell.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211863347) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Personalis, Inc. announced the publication of results from a major clinical study utilizing its NeXT Personal® test for ultrasensitive detection of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC). The study, published in the journal Cell, analyzed 431 NSCLC patients over a median of more than five years and demonstrated that the NeXT Personal test provides highly sensitive and specific detection of circulating tumor DNA (ctDNA) from diagnosis through long-term surveillance. Key findings include the ability to detect residual and recurrent cancer at multiple stages of patient care, with approximately 36-43% of detections in the ultrasensitive range. Additionally, the study found that patients who did not clear ctDNA during adjuvant chemotherapy were more than five times as likely to experience relapse compared to those who cleared ctDNA. The results have already been published and presented in Cell.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211863347) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7mtHGW:1","article_id":"2590511875","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590511875","pubTimestamp":1765461652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Personalis, Inc. announced the publication of results from a major clinical study utilizing its NeXT Personal test for ultrasensitive detection of molecular residual disease  in non-small cell lung cancer . The study, published in the journal Cell, analyzed 431 NSCLC patients over a median of more than five years and demonstrated that the NeXT Personal test provides highly sensitive and specific detection of circulating tumor DNA  from diagnosis through long-term surveillance. Key findings include the ability to detect residual and recurrent cancer at multiple stages of patient care, with approximately 36-43% of detections in the ultrasensitive range. Additionally, the study found that patients who did not clear ctDNA during adjuvant chemotherapy were more than five times as likely to experience relapse compared to those who cleared ctDNA. The results have already been published and presented in Cell.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSNL":"Personalis","BK4121":"生命科学工具和服务"},"translate_title":"Personalis NeXT个人测试在里程碑式研究中显示肺癌MRD检测的高灵敏度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":0.9},"content_text":"Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study\n    \n\n        Personalis, Inc. announced the publication of results from a major clinical study utilizing its NeXT Personal® test for ultrasensitive detection of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC). The study, published in the journal Cell, analyzed 431 NSCLC patients over a median of more than five years and demonstrated that the NeXT Personal test provides highly sensitive and specific detection of circulating tumor DNA (ctDNA) from diagnosis through long-term surveillance. Key findings include the ability to detect residual and recurrent cancer at multiple stages of patient care, with approximately 36-43% of detections in the ultrasensitive range. Additionally, the study found that patients who did not clear ctDNA during adjuvant chemotherapy were more than five times as likely to experience relapse compared to those who cleared ctDNA. The results have already been published and presented in Cell.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211863347) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590511875","isCrawlerRequest":true}